In the BioHarmony Drug Report Database

"Preview" Icon

Doxorubicin

Doxil (liposomal), Doxorubicin, Caelyx pegylated, Myocet (doxorubicin) is a small molecule pharmaceutical. Doxorubicin was first approved as Doxil (liposomal) on 1982-01-01. It is used to treat breast neoplasms, gastrointestinal neoplasms, hodgkin disease, lung neoplasms, and myeloid leukemia acute amongst others in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, multiple myeloma, and ovarian neoplasms. It is known to target DNA topoisomerase 2-alpha and sorcin.

 

Trade Name

 

Caelyx pegylated liposomal, Myocet, Myocet liposomal
 

Common Name

 

doxorubicin
 

ChEMBL ID

 

CHEMBL53463
 

Indication

 

breast neoplasms, gastrointestinal neoplasms, hodgkin disease, kaposi sarcoma, lung neoplasms, multiple myeloma, myeloid leukemia acute, neuroblastoma, osteosarcoma, ovarian neoplasms, precursor cell lymphoblastic leukemia-lymphoma, soft tissue neoplasms, thyroid neoplasms, urinary bladder neoplasms, wilms tumor
 

Drug Class

 

Antineoplastic antibiotics (daunorubicin type)

Image (chem structure or protein)

Doxorubicin structure rendering